Department of Periodontology and Operative Dentistry, University Hospital Münster, Münster, Germany.
Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
J Clin Periodontol. 2020 Jul;47(7):842-850. doi: 10.1111/jcpe.13288. Epub 2020 May 11.
The aim of this study was to evaluate the effect of non-surgical periodontal therapy on circulating levels of the systemic inflammation-associated biomarkers orosomucoid (ORM), high-sensitivity C-reactive protein (hsCRP), chemerin, and retinol-binding protein 4 (RBP4) in overweight or normal-weight patients with periodontitis at 27.5 months after therapy.
This exploratory subanalysis includes patients from the ABPARO-trial (ClinicalTrials.gov NCT00707369). The per-protocol collective provided untreated periodontitis patients with high (≥28 kg/m ) or moderate (21-24 kg/m ) BMI. Out of the per-protocol collective, 80 patients were randomly selected and stratified for BMI group, sex, and treatment group (antibiotics/placebo), resulting in 40 overweight and normal-weight patients. Patients received non-surgical periodontal therapy and maintenance at 3-month intervals. Plasma samples from baseline and 27.5 months following initial treatment were used to measure the concentrations of ORM, hsCRP, chemerin, and RBP4.
At the 27.5-month examination, ORM and hsCRP decreased noticeably in the overweight group (ORM: p = .001, hsCRP: p = .004) and normal-weight patients (ORM: p = .007, hsCRP: p < .001). Chemerin decreased in the overweight group (p = .048), and RBP4 concentrations remained stable.
Non-surgical periodontal therapy reduced systemically elevated inflammation-associated biomarkers in periodontitis patients. These improvements were more pronounced in overweight patients than in normal-weight patients.
本研究旨在评估非手术牙周治疗对牙周炎超重或正常体重患者治疗 27.5 个月后循环系统炎症相关生物标志物血清黏蛋白(ORM)、高敏 C 反应蛋白(hsCRP)、趋化素和视黄醇结合蛋白 4(RBP4)水平的影响。
本探索性亚分析包括来自 ABPARO 试验(ClinicalTrials.gov NCT00707369)的患者。方案集包括高(≥28kg/m²)或中度(21-24kg/m²)BMI 的未经治疗的牙周炎患者。在方案集中,随机选择 80 名患者并按 BMI 组、性别和治疗组(抗生素/安慰剂)分层,最终有 40 名超重和正常体重患者。患者接受非手术牙周治疗,并在 3 个月间隔进行维持治疗。使用基线和初始治疗后 27.5 个月的血浆样本测量 ORM、hsCRP、趋化素和 RBP4 的浓度。
在 27.5 个月的检查中,超重组(ORM:p=.001,hsCRP:p=.004)和正常体重患者(ORM:p=.007,hsCRP:p<.001)的 ORM 和 hsCRP 明显下降。趋化素在超重组下降(p=.048),而 RBP4 浓度保持稳定。
非手术牙周治疗可降低牙周炎患者系统性升高的炎症相关生物标志物。这些改善在超重患者中比在正常体重患者中更为明显。